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A B S T R A C T
This is a retrospective analysis of Fabry Outcome Survey data from children/adults (n= 677) receiving agal-
sidase alfa enzyme replacement therapy for a median of 3 years, examining cerebrovascular, cardiac, and renal
morbidity endpoints separately. Cardiac events occurred at younger ages than cerebrovascular or renal events,
cerebrovascular events were more frequent in females than males, and males were more likely to experience
cardiac and renal events at a younger age than females.
1. Introduction
Fabry disease (OMIM 301500) is a rare inherited lysosomal storage
disorder associated with reduced activity of α-galactosidase A (EC
3.2.1.22) [1] and characterized by signiﬁcant morbidity, including
renal impairment, cardiomyopathy, and cerebrovascular events [2–5].
In a recent analysis, we retrospectively compared long-term com-
posite morbidity outcomes in patients from the Fabry Outcome Survey
(FOS; sponsored by Shire) who were receiving agalsidase alfa enzyme
replacement therapy (ERT) with published outcomes in untreated pa-
tients with Fabry disease [6]. Long-term ERT appeared to slow the
progression of renal impairment and cardiomyopathy, and composite
morbidity events occurred later in treated patients. Our current objec-
tive was to further examine and describe long-term morbidity rates
separately by cerebrovascular, cardiac, and renal event origin in pa-
tients from FOS receiving agalsidase alfa ERT.
2. Materials and methods
Data were extracted from FOS for the period from database incep-
tion in 2001 to November 2012. Patient disposition is shown in Fig. A.1.
The FOS registry collects standardized information from patients who
are managed at participating centers and provide signed informed
consent. FOS has been approved by the ethics committee/institutional
review board of all participating centers and all procedures were in
accordance with the Declaration of Helsinki of 1975, revised in 2013.
Members of the FOS evaluable treated cohort (n= 677) had all
received agalsidase alfa ERT, including 86 children and 591 adults who
initiated treatment before or after FOS entry. Patients who had received
a kidney transplant or initiated dialysis before starting ERT were ex-
cluded, as were those who had received another ERT before FOS entry;
66 patients who left FOS were censored from the date they left.
Estimated glomerular ﬁltration rate (eGFR) was calculated in adults
(patients ≥18 years of age) only, using a four-variable Modiﬁcation of
Diet in Renal Disease equation [7]. Baseline left ventricular hyper-
trophy (LVH) was deﬁned by left ventricular mass index (LVMI)> 48
g/m2.7 in females or> 50 g/m2.7 in males. Baseline data regarding
proteinuria and Fabry phenotype were not available.
Morbidity as age at ﬁrst event was examined separately for cere-
brovascular, cardiac, and renal events. Cerebrovascular events included
stroke, transient ischemic attack, or prolonged reversible ischemic
neurologic deﬁcit. Cardiac events included myocardial infarction, car-
diac surgery, arrhythmia, angina, or heart failure. Renal events in-
cluded renal transplant, dialysis, or≥33% increase (in two consecutive
values) from baseline in serum creatinine. Kaplan-Meier analyses were
conducted for age at morbidity (from birth to ﬁrst event) with censoring
at last visit.
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3. Results
Baseline demographic and clinical characteristics are shown in
Table A.1. Among the 677 patients (360 male, 317 female) in the
overall FOS evaluable treated cohort, median (range) age at ﬁrst Fabry
disease symptom was 12 (0–72) years and median (range) age at di-
agnosis was 31 (0–79) years. Median (range) time on treatment (time
from treatment initiation to data extraction) was 3 (0–14) years. At
baseline, 63/447 (14.1% of adult patients with a baseline eGFR value
available) had eGFR < 60 mL/min/1.73 m2 and 143/330 (43.3% of
patients with a baseline LVMI value available) had LVH.
In the overall FOS evaluable treated cohort, the number and per-
centage of patients who did not experience an event during follow-up
was: cerebrovascular, 578 (85.4%); cardiac, 378 (55.8%); renal, 614
(90.7%); any morbidity event, 326 (48.2%; Table A.2). The Kaplan-
Meier point estimate (95% CI) for median age in years at ﬁrst event
was: cerebrovascular, 70.9 (68.1, not estimable [NE; because of the
small number of events]) in females and NE (64.9, NE) in males
(Fig. 1A); cardiac, 59.9 (56.8–61.9) in females and 50.6 (48.4–52.7) in
males (Fig. 1B); renal, NE (NE, NE) in females and 78.4 (70.3, NE) in
males (Fig. 1C).
Among female patients, the probability of not having a renal event
was relatively high even at advanced ages; for example, at age 75 years,
the probability of not having a renal event was ~90% in women and
~55% in men.
4. Discussion
The current analysis is an extension of our retrospective analysis
[6], which found that agalsidase alfa ERT appeared to slow the pro-
gression of renal impairment and LVH, and composite morbidity events
(including death) occurred later, in FOS patients receiving agalsidase
alfa ERT compared with published ﬁndings in untreated patients with
Fabry disease. The current work represents a purely descriptive analysis
of the status of treated patients; because of the lack of external com-
parator groups, no comparison of agalsidase alfa treated and untreated
patients was possible. Our ﬁndings are consistent with other published
analyses showing stable or improved cardiac or renal parameters in
patients receiving ERT with agalsidase alfa [3,8–12]. Compared with
similar analyses in the published literature [8,13–15], our analysis is
based on the largest dataset of clinical events in the long-term treat-
ment of Fabry disease to date. However, the number of renal events
recorded in the FOS database was still relatively small, limiting the
analysis of renal events and indicating that renal function is well
maintained over years of ERT.
Although the current analysis showed a somewhat higher propor-
tion of patients with an event than that reported by Germain et al. [8],
the deﬁnition of events was not comparable between these two ana-
lyses. For consistency with our previous analysis [6], which compared
treated patients from FOS with untreated patients in the published lit-
erature [16], the deﬁnition of events was broader in our FOS analysis
than in the analysis of Germain et al. [8], and therefore some of these
events were less severe (e.g., transient ischemic attack, prolonged re-
versible ischemic neurologic deﬁcit). In contrast, Germain et al. focused
on severe clinical events, which were deﬁned as “chronic dialysis,
kidney transplant, myocardial infarction, congestive heart failure,
major cardiac procedures (i.e., implantation of a balloon pump, cardi-
overter-deﬁbrillator or ﬁrst pacemaker; or bypass surgery), stroke and
death” [8].
Several limitations of our analysis should be noted. This was a ret-
rospective analysis of FOS registry data and the FOS patients were not
randomly selected, which may contribute to selection and/or ascer-
tainment bias. In general, registry analyses have a higher probability of
patient loss from the analysis because of the relative lack of data
completeness compared with randomized controlled trials.
Comparisons were not made with untreated patients from this registry;
consequently, no deﬁnitive conclusions can be made regarding eﬀec-
tiveness of ERT. FOS lacks a robust cohort of untreated patients for
comparison with treated patients. In general, untreated patients in FOS
have less severe disease and undergo fewer follow-up assessments; thus,
fewer outcome data are available [17]. Although LVMI is not itself a
clinical endpoint, LVH has been associated with both cardiac and renal
clinical outcomes in patients with Fabry disease [17,18]. A potential
source of bias is the censoring of patients who discontinued agalsidase
alfa ERT.
Over a median period of 3 years of agalsidase alfa ERT in this reg-
istry population of patients with long-standing Fabry disease, cardiac
events occurred more frequently and at younger ages than cere-
brovascular or renal events. Cerebrovascular events were more frequent
in females than in males. Males were more likely to experience cardiac
and renal events at a younger age than females. It is possible that the
presence of cardiac and renal events in males, and their subsequent
treatment, may decrease the incidence of later cerebrovascular events
relative to the incidence in females. Although we analyzed a cohort of
FOS patients with a median age of 46.2 years, one must also consider
that, from a US population perspective, the 10-year risk of stroke is
higher in middle-aged women aged 55 years than middle-aged men
aged 55 years [19]. The main determinant of stroke risk other than
advancing age is blood pressure [19], which an earlier analysis showed
to be uncontrolled in over half of untreated FOS patients at baseline
before declining after 2 years of agalsidase alfa ERT [20]. Analysis of
10-year outcomes in patients receiving agalsidase alfa ERT using de-
constructed composite events will shed more light on these observa-
tions.
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Age at first cardiac event on or after agalsidase alfa start (years)
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Age at first cerebrovascular event on or after agalsidase alfa start (years)
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Age at first renal event on or after agalsidase alfa start (years)
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Fig. 1. Age at ﬁrst morbidity (A) cerebrovascular event, (B) cardiac event, and (C) renal event. The 50th percentile point estimate in males for age at ﬁrst cerebrovascular event and in
females for age at ﬁrst renal event was not estimable (NE) because of the small number of events.
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Appendix A
Excluded:
Renal transplant or dialysis before ERT n = 37
Missing date for start of treatment n = 26
FOS evaluable treated cohort
n = 677
FOS all treated cohort
n = 740
Excluded:
Treatment with an ERT other than
agalsidase alfa before FOS entry n = 207
Not treated with agalsidase alfa n = 980
No confirmed informed consent n = 550
FOS total population as of data extraction on 15 November 2012
n = 2477
Fig. A.1. Disposition of patients. ERT, enzyme replacement therapy; FOS, Fabry Outcome Survey.
Table A.1











Race, n (%) n= 358 n= 311 n= 669
White 294 (82.1) 261 (83.9) 555 (83.0)
Black 0 (0) 1 (0.3) 1 (0.1)
Asian 58 (16.2) 40 (12.9) 98 (14.6)
Other 6 (1.7) 9 (2.9) 15 (2.2)
Age at data extract (years) n= 360 n= 317 n= 677
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Mean (SD) 40.8 (16.2) 50.6 (16.0) 45.4 (16.8)









Age at ﬁrst symptom (years) n= 287 n= 230 n= 517
Mean (SD) 14.3 (14.4) 24.9 (18.5) 19.0 (17.2)









Age at diagnosis (years) n= 341 n= 301 n= 642
Mean (SD) 27.1 (17.8) 39.1 (17.4) 32.7 (18.6)









Age at treatment initiation (years) n= 360 n= 317 n= 677
Mean (SD) 33.8 (16.1) 44.6 (16.2) 38.9 (17.0)









Time from initiation to last date of treatment (years) n= 360 n= 317 n= 677
Mean (SD) 4.3 (3.7) 3.9 (3.2) 4.1 (3.5)

















































BP, blood pressure; eGFR, estimated glomerular ﬁltration rate; FOS, Fabry Outcome Survey; FOS-MSSI, Fabry Outcome Survey Mainz Severity Score Index; IQR, interquartile range; LVH,
left ventricular hypertrophy.
Table A.2































FOS, Fabry Outcome Survey.
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